Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Vice President & Controller | April 30, 2019 | May 01, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
WEST PHARMACEUTICAL SERVICES INC
Report date April 30, 2019 · Filed May 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,020.3934 |
Ending reported balance
After 2019-04-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-04-30 · Exercise / conversion · Acquired 4,458 · Balance 33,478.3934 Row 2 · 2019-04-30 · Sale · Disposed 4,458 · Balance 29,020.3934 F1: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $123.00 to $123.07, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.34 · Expires 2020-03-22 | Direct | 5,000 |
Reported balance
After 2019-04-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-30 · Exercise / conversion · Disposed 4,458 · Balance 5,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $123.00 to $123.07, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2019 Filed May 1, 2019 14:21 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,458 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001562180-19-002450 · primarydocument.xml · derivative · entry 3 Malone Daniel · CIK 0001527326 · Vice President & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 4,458 shares Expires 2020-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2019 Filed May 1, 2019 14:21 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 4,458 | $123.03 | $548,477.10 |
DisclosureSEC source: 0001562180-19-002450 · primarydocument.xml · nonDerivative · entry 2 Malone Daniel · CIK 0001527326 · Vice President & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,020.3934 F1 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $123.00 to $123.07, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| April 30, 2019 Filed May 1, 2019 14:21 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 4,458 | $21.34 | $95,133.72 |
DisclosureSEC source: 0001562180-19-002450 · primarydocument.xml · nonDerivative · entry 1 Malone Daniel · CIK 0001527326 · Vice President & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,478.3934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:12 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 3,060 | $102.51 Strike: $102.51 | $313,680.60 |
DisclosureSEC source: 0001562180-19-001223 · primarydocument.xml · derivative · entry 2 Malone Daniel · CIK 0001527326 · Vice President & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,060 Underlying: Common Stock · 3,060 shares Expires 2029-02-19 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 19, 2020. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:12 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,281 | $102.51 | $131,315.31 |
DisclosureSEC source: 0001562180-19-001223 · primarydocument.xml · nonDerivative · entry 1 Malone Daniel · CIK 0001527326 · Vice President & Controller 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 6,735.45 F1 · shares: 2016 PSUs (PP15) award vesting. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 22:00 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $16.05 | $0.00 |
DisclosureSEC source: 0001562180-18-002970 · primarydocument.xml · derivative · entry 3 Malone Daniel · CIK 0001527326 · Vice President & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on February 24, 2010. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 22:00 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 5,000 | $97.24 | $486,200.00 |
DisclosureSEC source: 0001562180-18-002970 · primarydocument.xml · nonDerivative · entry 2 Malone Daniel · CIK 0001527326 · Vice President & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,020.3934 F1 · price: This transaction was executed in multiple trades at prices ranging from $97.11 USD to $97.28 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 22:00 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 5,000 | $16.05 | $80,225.00 |
DisclosureSEC source: 0001562180-18-002970 · primarydocument.xml · nonDerivative · entry 1 Malone Daniel · CIK 0001527326 · Vice President & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,020.3934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 22:46 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 3,760 | $89.64 Strike: $89.64 | $337,046.40 |
DisclosureSEC source: 0001562180-18-001154 · primarydocument.xml · derivative · entry 1 Malone Daniel · CIK 0001527326 · Vice President & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,760 Underlying: Common Stock · 3,760 shares Expires 2028-02-20 F1 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/20/2019 Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 23:30 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,250 | $93.00 | $116,250.00 |
DisclosureSEC source: 0001562180-18-001014 · primarydocument.xml · nonDerivative · entry 1 Malone Daniel · CIK 0001527326 · Vice President & Controller 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Deferred Compensation Plan Disclosed balance after: 5,454.45 F1 · shares: 2015 PSU (PP14) award vesting Read SEC document |
| May 02, 2017 Filed May 2, 2017 15:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,124 | $20.85 Strike: $20.85 | $85,985.40 |
DisclosureSEC source: 0001562180-17-001605 · primarydocument.xml · derivative · entry 3 Malone Daniel · CIK 0001527326 · Vice President & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,124 shares Expires 2018-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2017 Filed May 2, 2017 15:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 4,124 | $93.31 | $384,816.21 |
DisclosureSEC source: 0001562180-17-001605 · primarydocument.xml · nonDerivative · entry 2 Malone Daniel · CIK 0001527326 · Vice President & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,020.3934 F2 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $93.01 to $93.43, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| May 02, 2017 Filed May 2, 2017 15:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 4,124 | $20.85 | $85,985.40 |
DisclosureSEC source: 0001562180-17-001605 · primarydocument.xml · nonDerivative · entry 1 Malone Daniel · CIK 0001527326 · Vice President & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,144.3934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 20:21 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 4,184 | $83.47 Strike: $83.47 | $349,238.48 |
DisclosureSEC source: 0001562180-17-000853 · primarydocument.xml · derivative · entry 1 Malone Daniel · CIK 0001527326 · Vice President & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,184 Underlying: Common Stock · 4,184 shares Expires 2027-02-21 F1 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/21/2018. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 20:01 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,272 | $86.93 | $110,574.96 |
DisclosureSEC source: 0001562180-17-000736 · primarydocument.xml · nonDerivative · entry 2 Malone Daniel · CIK 0001527326 · Vice President & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,998.8866 F3 · shares: Bonus and incentive shares granted on 02/14/2017. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 20:01 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 943 | $86.93 | $81,974.99 |
DisclosureSEC source: 0001562180-17-000736 · primarydocument.xml · nonDerivative · entry 1 Malone Daniel · CIK 0001527326 · Vice President & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,726.8866 F1 · shares: Shares represent the portion of the Performance Share Unit Award granted in 2014 that have vested for period 13. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.